The goal of this study was to elucidate the transcriptional landscape of PTEN loss in PCa through the analysis of two large and very well clinically curated cohorts, for which PTEN and ERG status was assessed by clinical-grade IHC: The Natural History (NH) cohort, in which patients that underwent radical prostatectomy for clinically localized PCa did not receive neoadjuvant therapy or adjuvant hormonal therapy prior to documented distant metastases [19]; and the Health Professionals Follow-up Study (HPFS) cohort in which the patients were followed for over 25 years [20]. This evidence concerns the gene PTEN and posterior cortical atrophy.